CD274 and esophageal squamous cell carcinoma: Additionally, the clinical utility of biomarkers such as CPS and TPS remains uncertain, which may introduce bias when comparing PD-L1 expression outcomes across different PD-1 inhibitor trials in the second-line treatment of locally advanced ESCC.